Most gastrointestinal stromal tumors (GISTs) are driven by KIT or PDGFRA-activating mutations, but a small subset is associated with loss of function of the succinate dehydrogenase (SDH) complex of mitochondrial inner membrane proteins. This occurs by germline mutations of the SDH subunit genes and hitherto unknown mechanisms. SDHdeficient GISTs especially include pediatric GISTs and those associated with Carney triad (CT) or Carney-Stratakis syndromes (CSSs); the latter 2 also include paraganglioma as a component. SDH-deficient GISTs were identified in this study on the basis of immunohistochemical loss of succinate dehydrogenase subunit B (SDHB), which signals functional loss of the SDH complex. We found 66 SDH-deficient GISTs among 756 gastric GISTs, with an estimated frequency of 7.5% of unselected cases. Nearly, all gastric GISTs in patients <20 years, and a substantial percentage of those in patients <40 years, but only rare GISTs in older adults were SDH deficient. There was a female predominance of over 2:1. Two patients each had either pulmonary chondroma or paraganglioma (CT), but none of the examined cases had SDH germline mutations (CSS) or somatic KIT/PDGFRA or BRAF mutations. SDH-deficient GISTs were often multiple and typically showed plexiform muscularis propria involvement and epithelioid hypercellular morphology. They were consistently KIT-positive and DOG1/Ano 1-positive and almost always smooth muscle actin negative. Tumor size and mitotic activity varied, and the tumors were somewhat unpredictable with low mitotic rates developing metastases. Gastric recurrences occurred in 11 patients, and peritoneal and liver metastases occurred in 8 and 10 patients, respectively. Lymph node metastases were detected in 5 patients, but lymphovascular invasion was present in >50% of cases studied; these 2 were not related to adverse outcome. Seven patients died of disease, but many had long survivals, even with peritoneal or liver metastases. All 378 nongastric GISTs and 34 gastric non-GIST mesenchymal tumors were SDHB positive. SDH-deficient GISTs constitute a small subgroup of gastric GISTs; they usually occur in children and young adults, often have a chronic course similar to that of pediatric and CT GISTs, and have potential association with paraganglioma, necessitating long-term followup.
alteration causing biallelic inactivation of SDH in tumor cells typical of classic tumor suppressor genes. 22, 27, 34 In the nonhereditary Carney triad (CT) (GIST, paraganglioma, and pulmonary chondroma) and in most pediatric GISTs, the same end result occurs by currently unknown mechanisms. 34 Activation of pseudohypoxia signaling by overexpression of hypoxia-inducible factor 1 a is understood to be among the central events in the pathogenesis of SDH-deficient tumors. 7, 17, 18, 30 It has also been shown that silencing of SDHB expression induces tumor-like phenotypic traits in cell cultures. 6 SDH (succinate-coenzyme Q reductase or mitochondrial complex 2) consists of 4 subunit proteins, SDHA, SDHB, SDHC, and SDHD, localized in the inner mitochondrial membrane. This complex acts at the interphase of the tricarboxylic acid cycle and electron transport chain. One of the subunits, SDHB, is a hydrophilic ironsulfur protein, encoded by chromosomal DNA. 33 SDHB is normally ubiquitously expressed with granular cytoplasmic immunostaining reflecting its mitochondrial location. 9, 10 However, GISTs from patients with hereditary paraganglioma syndromes, the CSS, the CT, and pediatric GISTs in general have been found to be SDHB deficient on the basis of the small number of cases studied. 8, 10, 17 Loss of any subunit protein especially B, leads to the loss of SDHB expression due to destabilization of the SDH complex, and therefore SDHB loss is a marker for any biallelic loss of function of the SDH complex (SDH-deficient GIST). 11, 17 A similar role for SDH loss was previously discovered in paragangliomas. Many of them are also SDHB negative, generally reflecting loss-of-function germline mutations in one of the SDH genes, which, in combination with somatic loss of function of the other allele, lead to silencing of one of the SDH genes and functional loss of the SDH complex. 9, 35 In this study, we report 66 SDH-deficient gastric GISTs among 1134 GISTs and examine their pathology, prognosis, and genetic background.
MATERIALS AND METHODS
GISTs from the stomach (n = 756), small intestine (n = 265), rectum (n = 43), colon (n = 23), esophagus (n = 7), and extragastrointestinal locations (n = 40), a total 1134 GISTs, were immunohistochemically examined for SDHB expression (retention or loss). The cases were derived from different institutions and included a major component of second-opinion referrals. In most cases, immunostaining was performed on multitumor blocks containing 5 to 60 tumors. However, in 10 cases with limited material, unstained slides, hematoxylin and eosinstained slides, or slides with previous negative immunostains, especially from young patients, were processed for SDHB immunostaining. Twenty-six SDHB-negative cases were studied with an independent tissue array or conventional section, and a negative result was confirmed in each case. Some of the pediatric GISTs were previously reported, 24 as was the cohort of SDHB-positive neurofibromatosis 1 (NF1) associated GISTs. 37 In addition, 34 non-GIST mesenchymal tumors of the gastrointestinal tract were also studied for SDHB expression, including inflammatory myofibroblastic tumors, leiomyomas, leiomyosarcomas, schwannomas, plexiform fibromyxomas, and synovial sarcomas.
The primary mouse monoclonal antibody to SDHB, 21A11 (ABCAM, Cambridge, MA), was used at a dilution of 1:1000. Immunostaining was performed using the Leica BondMax autostainer (Leica Microsystems, Bannockburn, IL) utilizing the BondMax avidin biotin-free polymerbased detection system preceded by heat-induced epitope retrieval with Leica retrieval solution (alkaline buffer). Diaminobenzine was used as the chromogen. Only cases with positive internal control (vascular, lymphohematopoietic, smooth muscle, or epithelial elements) were considered informative. Only 1% of cases were deemed uninformative and were eliminated from further analysis.
Immunostaining was performed as follows: KIT (polyclonal antibody A4502; Dako Cytomation, Carpinteria, CA), diluted 1:250, and DOG1/anoctamin1 (monoclonal antibody, clone K9; Leica), diluted 1:100, Desmin (clone D33; Dako), diluted 1:50, and CD34 (clone QBEnd/10), prediluted (Ventana Medical Systems, Tucson, AZ) was performed following a similar epitope retrieval and procedure as described above. Smooth muscle actin (clone 1A4, Sigma Chemicals, St. Louis, MO), diluted 1:1600, and S100 protein (polyclonal, Dako Cytomation), diluted 1:1600, immunohistochemistry was performed similarly without epitope retrieval pretreatment.
The GISTs that were immunohistochemically negative for SDHB (all gastric) were analyzed histologically for the following details: mitotic count/50 high-power fields (HPF) (corresponding to 5 mm 2 ), plexiform/multinodular architecture, cellular components (epithelioid vs. spindle), cytologic atypia (especially pleomorphism), tumor necrosis, cytoplasmic vacuolization, nuclear palisading, lymphovascular invasion, and nodal metastases. Prognostic groups were assigned as previously described. 25 The gross features were recorded from available data, including tumor size, multiplicity, and possible metastases. Clinical follow-up was obtained from tumor registries, treating physicians, or in some cases from patients or family members. Follow-up information was available for 54 patients (range, <1 to 44 y; median, 14.7 y).
DNA was obtained from formalin-fixed and paraffin-embedded tumor tissue. Mutational analysis of KIT and PDGFRA genes was performed as previously described. 18 KIT exons 9, 11, 13, and 17 and PDGFRA exons 12, 14, and 18, mutational hot spots for GISTs, were polymerase chain reaction (PCR)-amplified, and the products were sequenced directly. BRAF mutation analysis was performed to detect the previously reported exon 15 mutant. 2, 16 Molecular studies of SDH genes were focused on selected coding and intronic sequences reportedly mutated in SDH-deficient GISTs. 17 
RESULTS

Demographics of the SDHB-Negative and SDHB-Positive GISTs
A total of 66 GISTs (all gastric), 8.7% of all 756 gastric GISTs studied, were immunohistochemically SDHB negative (SDHB-deficient GISTs). As 10 patients were selected by age for analysis, we estimate the true frequency among all gastric GISTs as 7.5%. This patient group consisted mainly of children and young adults but also included a small number of older adults (Fig. 1 ). The patients ranged in age from 8 to 77 years (median, 22 y; mean, 37 y). Thirty-three patients were 21 years or younger. There was a significant overall female predominance: 47 were female and 19 were male. This predominance was more in the age groups <21 years. However, there was an equal sex distribution in the age group Z30 years ( Table 1) .
The 66 SDHB-negative GISTs showed SDHB immunoreactivity only in non-neoplastic elements, such as vascular endothelial and smooth muscle cells, lymphohistiocytic cells, residual muscularis propria, or in epithelial elements such as hepatocytes. The tumor cells were negative for cytoplasmic granular staining, although they occasionally showed a weak focal cytoplasmic blush of positivity (Figs. 2A-D).
Most gastric GISTs, 690 of the total of 756 cases (91.2%), were immunohistochemically positive for SDHB and showed granular cytoplasmic staining of various intensities (Figs. 2E-H). Although SDHB-positive GISTs were rare in younger age groups, they overwhelmingly predominated in the older age groups ( Fig. 1 ). There were only 2 patients with SDHB-positive gastric GISTs under the age of 21 years: a 16-year-old boy and a 19-year-old woman.
All nongastric GISTs were SDHB positive ( Table 2 ). This included all small intestinal GISTs (n = 265), sporadic and NF1 associated, regardless of patient age. All esophageal, colorectal, and extragastrointestinal GISTs were also SDHB positive. With the exception of NF1-associated small intestinal GISTs (which contained a number of younger patients), the median age in each site-related group was around 60 years or above.
All 34 non-GIST mesenchymal tumors of the gastrointestinal tract examined were SDHB positive. These included 9 intramural leiomyomas, 8 leiomyosarcomas, 6 inflammatory myofibroblastic tumors, 7 gastric schwannomas, and 2 each of gastric plexiform fibromyxomas and synovial sarcomas.
Clinicopathologic Features of SDH-Deficient GISTs
The clinicopathologic features of patients with SDH-deficient GISTs are summarized in Table 1 . Most patients came to medical attention for symptoms related to gastrointestinal bleeding, and some were diagnosed on the basis of vague abdominal complaints or ulcer symptoms. In 1 patient with ulcer symptoms before the endoscopy era, the GIST diagnosis was delayed by several years until it was detected as a palpable mass. None of the patients had a family history of GIST or neurofibromatosis type 1.
When stated, the tumors were located in the antrum (n = 20), lesser curvature (n = 11), and posterior wall/ lesser sac (n = 2), and 1 each was located in the greater curvature/fundus, fundus, cardia, or upper stomach. Multiple synchronous tumors were present in at least 12 patients.
Other Tumors in Patients With SDHB-Deficient GISTs
Two patients, both children, had pulmonary chondroma, which was diagnosed simultaneously with GIST in 1 case and 1 year later in the other case, as it was originally suspected to be metastatic disease. Two different patients had paragangliomas. One had an adrenal pheochromocytoma 24 years before GIST, and another had a carotid body paraganglioma 25.5 years after the first GIST. One additional patient had renal onkocytoma 40 years after GIST. None of the patients were diagnosed with adrenal adenoma or esophageal leiomyoma.
Gross Features
Multiple synchronous GISTs were detected in 12 patients. The size of the dominant tumor varied from 1.5 to 12 cm (median, 5.0 cm). The GISTs were typically described as multinodular or sometimes bilobed masses, often divided by apparent fibrous septa ( Fig. 3 ). At least 7 larger tumors were centrally cystic. On sectioning, the tumors varied from yellowish to pale tan to pink and 
Histologic Features of SDHB-Deficient Gastric GISTs
The tumors commonly involved the muscularis propria as multiple apparently separate nodules, creating a "microplexiform" pattern ( Fig. 4A ). Such an arrangement was seen in nearly all cases specifically evaluated for this feature (32 of 34). Ulceration was present in 19 of 45 cases.
Epithelioid cytology dominated in 37 cases, 20 tumors had mixed epithelioid and spindle cells, 7 had spindle cells, and 1 had an extensively pleomorphic cytology. Most commonly, the tumors featured the epithelioid hypercellular type characterized by high cellularity and back-to-back cells in dense sheets (n = 27). Although most cases showed a rather uniform cytology, 4 tumors showed significant nuclear pleomorphism, and 2 of them had atypical mitoses (Fig. 4 ). Features commonly seen in adult GISTs, such as palisaded-vacuolated or sclerosing (spindle cell or epithelioid) morphology, were only rarely encountered. Nuclear palisading (typically vague) was seen in only 9 cases, but vacuolization was detectable in most cases, usually focally. Only 2 tumors had coagulation necrosis; both patients had long survivals. None of the tumors revealed calcification of mucosal invasion.
Two patients had omental/peritoneal micrometastases at presentation (Fig. 5A ). Lymph node metastases were encountered in 5 of 12 cases in which lymph nodes were present and reexamined in this study (Fig. 5B ). However, lymphovascular invasion around the tumor nodules was common and was seen in 17 of the 31 cases evaluated for this feature (Figs. 5C, D) . In some cases, sharply demarcated micronodules were, in fact, intravascular tumor deposits, similar to those seen in some gastric glomus tumors.
Immunohistochemically, nearly all examined cases were extensively positive for KIT (52 of 53) and DOG1/ Ano 1 (31 of 31), with >50% of tumor cells positive in each case. CD34 was detected in 44 of 52 cases (usually extensively) but muscle markers only rarely: smooth muscle actin in 1 of 51 cases (focally) and desmin in 1 of 49 cases (in 3% of tumor cells). None of the 47 examined cases were S100 protein positive.
Mutation Analysis
All samples evaluated for KIT exons 9 (n = 30), 11 (n = 31), 13 (n = 30), and 17 (n = 31) and for PDGFRA exons 12 (n = 29), 14 (n = 24), and 18 (n = 29) were wild type. This was also true for BRAF exon 15 (n = 16). No mutations were found in SDHB exons 1 (n = 22), 3 (n = 21), 4 (n = 22), 6 (n = 20), and 7 (n = 22), in SDHC exons 1 (n = 24) and 5 (n = 23), and in SDHD exon 1 (n = 23) coding sequences. All flanking intronic sequences except the exon/intron 6 boundary were evaluated. The latter could not be examined because of a lack of a compatible primer system for assaying formalin-fixed and paraffin-embedded tissue.
Follow-Up
Eleven patients developed 1 or more gastric recurrences or second primary tumors <1 to 33 years from presentation and underwent subtotal or total gastrectomy. Only one of these patients had liver metastases. Ten patients had liver metastasis, 3 of them at presentation. The longest interval from primary tumor to liver metastasis was 42 years. Eight patients had abdominal soft tissue metastases. Only one of them, who also had liver metastases, died of disease, but 3 patients survived for 10 to 17 years after peritoneal metastases. To date, 7 patients have died, all of them but 1 with known liver metastases, but 3 have survived for 10 to 18 years with liver metastases. Four of the 7 patients who died of tumor were male patients. Two patients who died of disease had mitotic rates <5/50 HPFs. Four patients were known to have received imatinib mesylate for 6 months to 7 years, and 1 patient underwent excision of abdominal metastases subsequent to imatinib response. No patient was known to have received sunitib malate.
DISCUSSION
In this study we clinicopathologically evaluated 66 SDH-deficient gastric GISTs, defined here by immunohistochemical negativity for SDHB, one of the normally ubiquitously expressed subunits of the SDH complex. On the basis of knowledge of the impact of loss of any SDH subunitsFinactivation of the entire SDH complex in other tumors associated with SDH deficiency, especially paragangliomas 11, 17 Fit is appropriate to designate this group as SDH-deficient GISTs.
We found SDH-deficient GISTs exclusively among gastric GISTs (66 of 756, 8.7%). However, this overestimates the true frequency, as the analysis was in part targeted to GISTs of young patients. On the basis of an unselected sample, we estimate that the true frequency of 10 Although there was an overall female predominance, the sex distribution was equal in age groups >30 years in our study.
There are a number of histologic clues to identify SDH-negative status. These include epithelial hypercellular histology, plexiform growth pattern in the muscularis propria, and lymphovascular invasion and lymph node metastases that are otherwise rare in gastric GISTs. In fact, the "plexiform" muscularis propria involvement resembles that which is often seen in gastric glomus tumors and may be intravascular in some of the nodules. 23 Similar patterns were recently also reported in rare adult GISTs resembling pediatric GISTs, but their SDHB status was not known. 32 Immunohistochemically, SDH-deficient GISTs are distinctive for strong KIT expression, in contrast to many gastric epithelioid GISTs that show weaker KIT expression. They are also more often CD34 positive compared with gastric epithelioid GISTs but almost never express a smooth muscle actin that is present in 23% of gastric GISTs, at least focally. 25 A molecular genetic clue to SDH-deficient GISTs is lack of KIT and PDGFRA mutations (wild type), found here in all analyzed SDH-deficient GISTS, similar to previous observations in a smaller number of cases. 17 In addition, these tumors seem to be unrelated to the rare KIT/PDGFRA-wild type GISTs carrying BRAF mutations found in adult patients, more often with intestinal GISTs. 2, 16 Clinical behavior of SDH-deficient GISTs largely mirrors pediatric and CT GISTs because of their pre-dominant occurrence at a young age. In our study cohort, 10 of 54 patients with follow-up (19%) developed liver metastases, and 7 patients died of disease. Many patients were alive with disease during long-term follow-up. Long latency from primary tumor to metastasis is common, and the longest interval from primary tumor to liver metastasis was 42 years in our study, illustrating the chronic course and need for life-long follow-up. Gastric recurrences, very rare in adult gastric GISTs, are common in SDH-deficient GISTs, often ultimately leading to subtotal gastrectomy; they do not seem to have adverse prognostic significance. Neither are lymphovascular invasion, lymph node metastases, and peritoneal micrometastases ominous signs in this group, as many patients diagnosed with them survived for a long period of time.
SDH-deficient GISTs are unpredictable, and metastatic disease may occur in tumors with favorable histologic parameters; 2 such patients died of disease. In our experience, many patients with metastatic GISTs r5 cm with mitotic counts r5/50 HPFs (group 2 GISTs) are SDH-deficient GISTs. In contrast, some patients with SDH-deficient GISTs with mitotic activity in excess of 10/ 50 HPFs have uneventful survival, again illustrating their unpredictability. The fact that 4 of 7 patients who died of tumor were male in this heavily female dominated group may suggest that male patients have a more aggressive course of disease. The very small number of older adults with SDH-deficient GISTs limits prognostic conclusions, although all patients except 1 had a favorable outcome. In general, SDH-deficient GISTs resemble CT-associated and pediatric GISTs with regard to the following characteristics: tumor multiplicity, predilection to gastric antrum, potential occurrence of nodal metastases, chronic nature, and somewhat unpredictable course but ultimately low, long-term tumor mortality. 5, 24, 31, 38 The CT (gastric GIST, pulmonary chondroma, and paraganglioma) is a nonhereditary tumor syndrome including gastric GIST, pulmonary chondroma, and paraganglioma at varying time intervals. It has a strong predilection to young female patients. 5, 38 In this study, we identified only 2 patients with pulmonary chondroma and 2 other patients with paraganglioma. Even though the frequency of the CT may be underestimated in our series, the findings suggest that the CT is not very common among SDH-deficient GISTs. CT patients do not have SDH germline mutations, but SDH deficiency may be mediated by allelic losses in SDH; further, losses in chromosome 1p36, the locus of SDHB, may be the alternative mechanism for loss of function of the SDH complex. 21 The CSS is a rare hereditary syndrome combining gastric GIST and paraganglioma. In contrast to the CT, it has a more equal sex distribution. The pathogenesis is based on a loss-of-function germline mutation in SDH subunits B, C, or D and on functional loss of the other allele based on currently poorly understood mechanisms. 27, 28 Lack of familial tumor history and SDHB, C, or D (germline) mutations (analyzed in 10 patients in this study) suggests that SDHB-deficient GISTs are not commonly associated with CSS. However, we were not able to analyze DNA from 2 male patients with GIST and paraganglioma, both of whom were good candidates for CSS. However, 54% of patients with paragangliomas, commonly SDH-deficient tumors, were found to have germline SDH mutations in 1 study. 3 In their rarity of SDH germline mutations, despite SDH-deficient status, GISTs differ from paragangliomas, for which SDH deficiency generally signals a germline mutation. 35 Very recently, loss-of-function SDHA germline mutations were reported in 2 gastric KIT/PDGFRA wild-type GISTs, 26 indicating that mutations of this subunit should also be screened in SDH-negative GISTs. SDHA mutations were previously found in 1 patient with a cathecholamine-secreting adrenal paraganglioma. 4 Previously, SDHA loss-of-function mutation was reported in the Leigh syndrome featuring a severe neurodegenerative disorder. 15 Renal onkocytoma was diagnosed in 1 patient with an SDH-deficient GIST. Renal cell carcinoma has been reported to be associated with SDHB paraganglioma syndrome, and this tumor is also otherwise known to be associated with the pseudohypoxia pathway. 36 Esopha-geal leiomyoma or adrenal adenoma, other tumors seen in Carney Triad, 5 were not seen in our patients.
The pathogenesis-based definition, SDH-deficient GIST, common to GISTs of the CT, the CSS, and pediatric GISTs in general, obtained by a single immunostain for SDHB, seems to be more efficient than the identification of a syndrome based on accompanying tumors, paragangliomas, and pulmonary chondromas, or young age only. First, different components of these syndromes can present over a long period of time, making life-long follow-up necessary to observe the complete syndrome phenotype. Second, on the basis of knowledge of the related paraganglioma syndromes also associated with SDH deficiency, these syndromes may have incompleteto-low penetrance, perhaps in only 30%, making it more difficult to observe familial disease without germline mutation analysis. 13 Third, there are pediatric GISTs other than SDH-deficient GISTs; these include few and gastric and the very rare nongastric GISTs at young age. Similar gene expression profiles reported in CT, CSS, pediatric GISTs, and a small number of adult GISTs also seem to support the unifying concept of SDH-deficient GIST. 1 SDHB-deficient GISTs seem to exclusively occur in the stomach, and none of the GISTs from other locations were SDHB negative. This included the rare nongastric GISTs in young populations, NF1-associated GISTs, and sporadic, nongastric wild-type GISTs, the pathogenesis of which remains poorly understood. However, 1 report described 2 small intestinal (jejunal) GISTs in paraganglioma patients. 29 Although these cases were negative for SDH subunit mutations, immunohistochemical testing for SDHB was not yet available; therefore, it is yet to be determined whether these jejunal GISTs were SDH deficient.
For treatment, patients with SDH-deficient GISTs should undergo complete tumor resection with attention to secondary lesions and peritoneal and nodal metastases. For adjuvant therapy, they may require a different approach than KIT/PDGFRA-mutated GISTs that typically respond to imatinib mesylate, the first-line KIT tyrosine kinase inhibitor. Instead, second-generation tyrosine kinase inhibitors, such as sunitib malate, may be more effective, as noted for pediatric GISTs. 1 Life-long follow-up is necessary for the potential of liver metastases and accompanying tumors, especially paragangliomas, for which also radiologic screening might be indicated. In this retrospective study, only a few patients received imatinib for some periods of time, and none received sunitinib; hence, data are insufficient for further comments on the effectiveness of tyrosine kinase inhibitor treatment, especially in view of the generally slow natural course of disease.
In conclusion, we analyzed a series of 66 gastric SDHdeficient GISTs. Most patients were young, with a small population of older adults. Only 4 patients had accompanying tumors defining the CT, and none of the patients were found to have germline mutations of SDH subunits defining the CSS. SDH-deficient GISTs are KIT/PDGFRA wild type and typically have plexiform muscularis propria involvement, epithelioid morphology, and lymphovascular invasion; some also have lymph node metastases. Multiple synchronous or asynchronous tumors are common, leading to gastric recurrences. Potential, somewhat unpredictable, development of liver metastases (in 20% of patients) after long latency and asynchronous paragangliomas necessitates long-term follow-up.
